Cancer Stat Facts: Myeloma. https://seer.cancer.gov/seertools/hemelymph/ (2022).

D’Agostino M, Bertamini L, Oliva S, Boccadoro M, Gay F. Pursuing a curative approach in multiple myeloma: a review of new therapeutic strategies. Cancers. 2019;11:2015. https://doi.org/10.3390/cancers11122015.

Article  CAS  Google Scholar 

Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl J Med. 2015;373:621–31. https://doi.org/10.1056/nejmoa1505654.

Article  CAS  Google Scholar 

Kazmi SM, Nusrat M, Gunaydin H, Cornelison AM, Shah N, Kebriaei P, et al. Outcomes among high-risk and standard-risk multiple myeloma patients treated with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation. Clin Lymphoma Myeloma Leuk. 2015;15:687–93. https://doi.org/10.1016/j.clml.2015.07.641.

Article  Google Scholar 

Jadoon Y, Siddiqui MA. Immunotherapy in multiple myeloma. Cancer Treat Res Commun. 2021;29:100468. https://doi.org/10.1016/j.ctarc.2021.100468.

Article  Google Scholar 

Verkleij CPM, Korst CLBM, van de Donk NWCJ. Immunotherapy in multiple myeloma: when, where, and for who? Curr Opin Oncol. 2020;32:664–71. https://doi.org/10.1097/CCO.0000000000000677.

Article  CAS  Google Scholar 

Le Calvez B, Moreau P, Touzeau C. Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options. Expert Opin Investig Drugs. 2021;30:965–73. https://doi.org/10.1080/13543784.2021.1955103.

Article  CAS  Google Scholar 

Nadeem O, Tai T, Anderson KC. Immunotherapeutic and targeted approaches in multiple myeloma. ImmunoTargets Ther. 2020;9:201–15. https://doi.org/10.2147/ITT.S240886.

Article  CAS  Google Scholar 

Kegyes D, Constantinescu C, Vrancken L, Rasche L, Gregoire C, Tigu B, et al. Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? J Hematol Oncol. 2022;15:78 https://doi.org/10.1186/s13045-022-01296-2.

Article  CAS  Google Scholar 

Timmers M, Roex G, Wang Y, Campillo-Davo D, Van Tendeloo VFI, Chu Y, et al. Chimeric antigen receptor-modified T cell therapy in multiple myeloma: beyond B cell maturation antigen. Front Immunol. 2019;10:1613. https://doi.org/10.3389/fimmu.2019.01613.

Article  CAS  Google Scholar 

Poondla N, Sheykhhasan M, Akbari M, Samadi P, Kalhor N, Manoochehri H. The promise of CAR T-cell therapy for the treatment of cancer stem cells: a short review. Curr Stem Cell Res Ther. 2022;17:400–6. https://doi.org/10.2174/1574888X17666220217101817.

Article  CAS  Google Scholar 

Sheykhhasan M, Manoochehri H, Dama P. Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study. Cancer Gene Ther. 2022;29:1080–96. https://doi.org/10.1038/s41417-021-00418-1.

Article  CAS  Google Scholar 

Turtle CJ, Hanafi L-A, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126:2123–38. https://doi.org/10.1172/JCI85309.

Article  Google Scholar 

Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989;86:10024–8. https://doi.org/10.1073/pnas.86.24.10024.

Article  CAS  Google Scholar 

Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388–98. https://doi.org/10.1158/2159-8290.CD-12-0548.

Article  CAS  Google Scholar 

Park JH, Brentjens RJ. Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med. 2010;9:277–88.

Google Scholar 

Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94:S3–S9. https://doi.org/10.1002/ajh.25418.

Article  CAS  Google Scholar 

Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. Trends Immunol. 2015;36:494–502. https://doi.org/10.1016/j.it.2015.06.004.

Article  CAS  Google Scholar 

Abate-Daga D, Davila ML. CAR models: next-generation CAR modifications for enhanced T-cell function. Mol Ther Oncolytics. 2016;3:16014. https://doi.org/10.1038/mto.2016.14.

Article  CAS  Google Scholar 

Akhoundi M, Mohammadi M, Sahraei SS, Sheykhhasan M, Fayazi N. CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities. Cell Oncol. 2021;44:495–523. https://doi.org/10.1007/s13402-021-00593-1.

Article  CAS  Google Scholar 

Leivas A, Valeri A, Córdoba L, Ortiz A, Fernández L, Pérez M, et al. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer J. 2021;11:1–11. https://doi.org/10.1038/s41408-021-00537-w.

Article  Google Scholar 

Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl J Med. 2013;368:1509–18. https://doi.org/10.1056/NEJMoa1215134.

Article  CAS  Google Scholar 

Duan D, Wang K, Wei C, Feng D, Liu Y, He Q, et al. The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory/recurrent multiple myeloma. Front Immunol. 2021;12:609421. https://doi.org/10.3389/fimmu.2021.609421.

Article  CAS  Google Scholar 

Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing mechanisms of chimeric antigen receptor (CAR) T cells. International J Mol Sci. https://doi.org/10.3390/ijms20061283. (2019).

Johnson LA, June CH. Driving gene-engineered T cell immunotherapy of cancer. Cell Res. 2017;27:38–58. https://doi.org/10.1038/cr.2016.154.

Article  CAS  Google Scholar 

Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B. 2018;8:539–51. https://doi.org/10.1016/j.apsb.2018.03.001.

Article  Google Scholar 

Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24:20–8. https://doi.org/10.1038/nm.4441.

Article  CAS  Google Scholar 

Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112:2261–71. https://doi.org/10.1182/blood-2007-12-128843.

Article  CAS  Google Scholar 

Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19:2048–60. https://doi.org/10.1158/1078-0432.CCR-12-2422.

Article  CAS  Google Scholar 

Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell. 2017;31:396–410. https://doi.org/10.1016/j.ccell.2017.02.002.

Article  CAS  Google Scholar 

Friedman KM, Garrett TE, Evans JW, Horton HM, Latimer HJ, Seidel SL, et al. Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells. Hum Gene Ther. 2018;29:585–601. https://doi.org/10.1089/hum.2018.001.

Article  CAS  Google Scholar 

Cho S-F, Anderson KC, Tai Y-T. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol. 2018. https://doi.org/10.3389/fimmu.2018.01821.

Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128:1688–700. https://doi.org/10.1182/blood-2016-04-711903.

Article  CAS  Google Scholar 

Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36:2267–80. https://doi.org/10.1200/JCO.2018.77.8084.

Article  CAS  Google Scholar 

Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl J Med. 2019;380:1726–37. https://doi.org/10.1056/NEJMoa1817226.

Article  CAS  Google Scholar 

Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, et al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: updated results from phase 1 CRB-401 study. Blood. 2020;136:26–7. https://doi.org/10.1182/blood-2020-134324.

Article  Google Scholar 

Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl J Med. 2021;384:705–16. https://doi.org/10.1056/NEJMoa2024850.

Article  CAS  Google Scholar 

Shah N, Mojebi A, Ayers D, Cope S, Dhanasiri S, Davies FE, et al. Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma. J Comp Eff Res. 2022;11:737–49. https://doi.org/10.2217/cer-2022-0045.

Article  CAS  Google Scholar 

Anderson JLD, Munshi NC, Shah N, Jagannath S, Berdeja JG, Lonial S, et al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: updated KarMMa results. J Clin Oncol. 2021;39:8016 https://doi.org/10.1200/JCO.2021.39.15_suppl.8016.

Article  Google Scholar 

Anderson LD Jr, Shah N, Jagannath S, Berdeja JG, Lonial S, Raje N, et al. OAB-027: idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa. Clin Lymphoma, Myeloma Leuk. 2021;21:S17–S8. https://doi.org/10.1016/S2152-2650(21)02101-7

Article  Google Scholar 

Delforge M, Shah N, Rodríguez-Otero P, Braverman J, Dhanda D, Shi L, et al. Updated health-related quality of life results from the KarMMa clinical study in patients with relapsed and refractory multiple myeloma treated with the B-cell maturation antigen-directed chimeric antigen receptor T cell therapy idecabtagene vicleucel (ide-cel, bb2121). Blood. 2021;138:2835 https://doi.org/10.1182/blood-2021-145155.

Article